Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis  by Nishii, Mototsugu et al.
S
P
M
I
N
S
M
r
f
t
t
m
c
m
p
m
r
i
t
S
a
U
P
g
J
a
Journal of the American College of Cardiology Vol. 44, No. 6, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.055Myocarditis
erum Levels of Interleukin-10 on Admission as a
rognostic Predictor of Human Fulminant Myocarditis
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chiro Takeuchi, MD, Hironari Nakano, MD, Toshimi Koitabashi, MD, Jun-ichi Nakahata, MD,
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OBJECTIVES We assessed the significance of serum cytokine levels in patients with fulminant myocarditis.
BACKGROUND Although many investigations have demonstrated the crucial role of cytokines in the
development of myocarditis, it remains uncertain whether serum levels of cytokines enable
one to predict the prognosis of human myocarditis, especially concerning cardiogenic shock
(CS) requiring a mechanical cardiopulmonary support system (MCSS).
METHODS We studied 22 consecutive patients with fulminant myocarditis and compared them with 15
patients with acute myocardial infarction (AMI) requiring MCSS. The patients with
myocarditis were classified into three groups: eight patients with CS requiring MCSS on
admission (group 1); six patients who unexpectedly lapsed into CS requiring MCSS more
than two days after catecholamine had been initiated (group 2); and eight patients without
MCSS (group 3). Furthermore, 14 patients with myocarditis requiring MCSS were divided
into a fatal group (n 5) and a survival group (n 9). Biochemical markers, including serum
cytokine levels and hemodynamic variables on admission, were analyzed.
RESULTS Serum levels of interleukin (IL)-10 and tumor necrosis factor-alpha, but not other cytokines,
were significantly higher in myocarditis than in AMI. Only serum levels of IL-10 were
significantly higher in group 1 and 2 than in group 3 (49.1  37.5/20.7  17.6 pg/ml vs. 2.4
 1.1 pg/ml; p  0.0008/0.0012). Serum IL-10 levels were also significantly higher in the
fatal group than in the survival group with myocarditis (74.0  27.0 pg/ml vs. 16.4  8.8
pg/ml; p  0.003).
CONCLUSIONS Serum IL-10 levels on admission enabled one to predict subsequent CS requiring MCSS and
mortality of fulminant myocarditis patients. (J Am Coll Cardiol 2004;44:1292–7) © 2004
by the American College of Cardiology Foundationh
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pcCarthy et al. (1) and Lieberman et al. (2) have presented
emarkable reports that the prognosis of patients with
ulminant myocarditis, who suffered from cardiac dysfunc-
ion and required intensive circulatory supports, is better
han that of patients with non-fulminant myocarditis. A
onophasic clinical course, that is, prompt recovery upon
onclusion of the acute phase often seen in fulminant
yocarditis, may contribute to a favorable outcome (3). The
See page 1298
oint to be argued in the aforementioned studies is that
ost of the included patients with fulminant myocarditis
equired only high-dose catecholamine without a mechan-
cal cardiopulmonary support system (MCSS). Although
he use of MCSS has currently been widespread to maintain
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kccepted January 20, 2004.emodynamics in patients with fulminant myocarditis who
apse into cardiogenic shock (CS) without effective response
f the administration of high-dose catecholamine (4,5), the
rognosis of such patients requiring MCSS is still not
atisfactory (6). The fundamental concept to improve sur-
ival in patients with fulminant myocarditis with deterio-
ated hemodynamics despite catecholamine use must be
ppropriately introduced together with adjustment of
CSS facilitating the recovery from circulatory failure (6).
owever, there have been no reports concerning the clinical
arameters detected in the acute phase to predict whether
CSS is required in cases with fulminant myocarditis.
The significance of cytokines in the pathomechanism of
uman myocarditis remains uncertain. It has been demon-
trated in experimental myocarditis that cytokines such as
nterleukin (IL)-10, IL-12, tumor necrosis factor (TNF)-
lpha and interferon (IFN)-gamma play a crucial role in the
evelopment of myocarditis (7–12). In addition, some
eports have suggested that serum levels of cytokines were
levated in human myocarditis (13,14). These findings
mply that cytokines may be a candidate for determining the
rognosis in acute myocarditis.
In the present study, we examined whether serum cyto-ines levels as well as various clinical parameters, including
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September 15, 2004:1292–7 IL-10 in Human Fulminant Myocarditisemodynamic variables and biochemical laboratory data on
dmission, enable one to determine the subsequent prog-
osis in fulminant myocarditis patients.
ETHODS
ubjects. Twenty-two consecutive patients admitted to
itasato University Hospital during 1995 to 2001, classified
s fulminant myocarditis according to the criteria of Lieber-
an et al. (2), were included in this study. All of the patients
ere diagnosed as having active myocarditis histopatholog-
cally either from endomyocardial biopsy or autopsy accord-
ng to the Dallas criteria (15). Table 1 shows the individual
aseline data of patients with fulminant myocarditis in-
luded in this study. A viral study was performed in nine
atients by measurement of neutralizing antibody titers in a
aired sample. Three patients were positive for Coxsack-
evirus B3. Histologic examination demonstrated that only
ne (5%) or two patients (9%) were diagnosed as having
iant cell myocarditis or eosinophilic myocarditis, respec-
ively, whereas the rest of the patients (86%) were diagnosed
s having lymphocytic myocarditis. All of the patients
uffered from flu-like symptoms one to two weeks before the
istinct onset of cardiac symptoms and received treatment
ith high-dose catecholamine immediately after hospital
dmission owing to circulatory failure.
Based on the clinical course, the present study population
f patients with fulminant myocarditis was classified into
hree groups as follows: eight patients who had already
apsed into CS and required MCSS with high-dose cate-
holamine on admission (group 1); six patients who unex-
ectedly lapsed into CS requiring MCSS more than two
ays after high-dose catecholamine had been initiated
group 2); and eight patients who required only high-dose
atecholamine but not MCSS (group 3). In addition,
atients requiring MCSS were divided into a fatal group (n
5) and a survival group (n  9). Non-survivors died from
efractory heart failure (HF) or fatal arrhythmia, whereas all
f the survivors could be discharged with improvement of
ardiac symptoms. The MCSS was introduced according to
he therapeutic guidelines from the Scientific Committee of
Abbreviations and Acronyms
AMI  acute myocardial infarction
BNP  brain natriuretic peptide
CS  cardiogenic shock
cTnT  cardiac troponin T
HF  heart failure
IFN  interferon
IL  interleukin
MCSS  mechanical cardiopulmonary support system
TNF  tumor necrosis factorhe Japanese Circulation Society (6). Briefly, if the patient (id not recover from circulatory failure despite the admin-
stration of enough cardiotonic or vasodepressor drugs and
he subsequent use of an intra-aortic balloon pump, percu-
aneous cardiopulmonary support was introduced.
Control subjects were 15 consecutive patients with acute
yocardial infarction (AMI) without ventricular rupture,
ho required MCSS for CS during the disease course.
here were 5 non-survivors, who died from CS, and 10
urvivors.
lood sampling and biochemical assays. Blood samples
ere taken from the radial artery before any therapies on
dmission. Serum was immediately separated from the
lood element by centrifugation at 400  g for 10 min.
liquots were stored at 80°C until assay. Intra-assay and
nter-assay coefficients of variation were 10%.
Levels of serum cardiac troponin T (cTnT) were mea-
ured using the third-generation Enzyme cTnT assay
Roche, Indianapolis, Indiana). High-sensitivity assays for
-reactive protein were performed according to methods
escribed by the manufacturer (Behring Diagnostic, West-
ood, Massachusetts), and plasma brain natriuretic peptide
BNP) levels were measured with a specific immunoradio-
etric assay for human BNP (Shionoria, Osaka, Japan).
erum levels of IL-10, IL-12, TNF-alpha, and IFN-
amma were measured according to the methods of the
anufacturer of the enzyme-linked immunoabsorbent assay
BioSource, Camarillo, California). The normal upper limit
f the assay was as follows: 2 pg/ml for IL-10; 106 pg/ml for
L-12; 3.1 pg/ml for TNF-alpha; and 20 pg/ml for IFN-
amma.
emodynamic measurements. Hemodynamic variables,
ncluding heart rate, systolic blood pressure, cardiac output,
ulmonary capillary wedge pressure, central venous pres-
ure, and venous saturation, were measured together with
lood gas analysis using direct pressure monitoring from the
adial artery and the Swan-Ganz catheter technique on
dmission before any therapies were undertaken.
tatistical analysis. Data were statistically analyzed by use
f the software program StatView J-5.0 (Abacus Concepts,
erkeley, California). Comparisons of several clinical pa-
ameters and serum levels of cytokine between the fulmi-
ant myocarditis group and the AMI group, as well as
mong the subgroups of fulminant myocarditis, were per-
ormed with the Mann-Whitney U test. Each value is
hown as the mean  SD. We judged that values showed a
tatistically significant difference at p  0.05.
ESULTS
ortality of cases with fulminant myocarditis. The mor-
ality of group 1 (4 of 8; 50%) was higher than that of group
(1 of 6; 17%). All patients in group 3 survived with
mprovement of cardiac symptoms during the disease course
Table 1).
Table 1. Individual Baseline Information of Patients With Fulminant Myocarditis on Admission
Case Age Gender Day Hist
CS on
AD IABP PCPS
SBP
(mm Hg)
CI
(min/m2)
PCWP
(mm Hg)
SVO2
%
CVP
(mm Hg)
cTnT
(ng/ml)
BNP
(pg/ml)
CRP
(g/dl)
IL-10
(pg/ml)
IL-12
(pg/ml)
TNF-
(pg/ml) Virus Outcome
1 83 M 4 L  on AD on AD 72 0.9 20 52 14 2.82 520 11,100 70.9 87.9 22.0 n.e. Fatal
2 77 M 10 L  on AD on AD 70 1.2 22 58 15 4.08 680 17,000 42.3 260.0 55.2 CVB3 Fatal
3 36 F 4 G  on AD on AD 70 1.2 18 58 10 2.42 780 7,395 90.4 280.0 23.8 n.e. Fatal
4 55 F 8 L  p AD p AD 112 1.9 14 74 8 0.44 160 9,779 56.2 140.0 26.8 CVB3 Fatal
5 60 F 12 L  on AD on AD 80 0.7 28 56 16 4.69 600 11,500 110.0 120.0 54.3 n.e. Fatal
6 46 M 6 L  on AD on AD 72 1.0 33 56 15 3.99 430 3,500 6.6 7.8 22.3  Survival
7 62 M 5 L  p AD p AD 100 1.9 12 77 9 0.66 300 2,390 16.1 11.0 34.2 CVB3 Survival
8 45 M 3 L  p AD p AD 100 2.1 16 78 14 1.97 296 6,777 13.2 28.3 44.2 n.e. Survival
9 32 M 14 L  p AD p AD 110 1.1 13 60 12 2.6 362 2,225 10.1 25.1 20.7 n.e. Survival
10 45 F 6 L  on AD on AD 72 1.3 22 58 16 2.32 820 1,350 19.7 174.2 17.2  Survival
11 51 M 7 L  on AD on AD 70 0.7 20 58 15 2.82 800 12,000 37.6 191.9 16.2 n.e. Survival
12 23 M 8 L  p AD p AD 112 2.2 11 77 10 2.57 270 22,124 16.1 19.6 18.6 n.e. Survival
13 38 F 6 L  p AD p AD 90 2.4 12 78 7 1.1 96 561 12.3 14.9 16.1 n.e. Survival
14 41 F 3 L  on AD p AD 80 1.2 20 58 13 0.9 123 3,450 15.5 36.2 20.1 n.e. Survival
15 43 M 12 L    110 1.8 10 70 5 2.38 300 359 2.1 16.0 8.6 n.e. Survival
16 77 M 10 L    96 2.3 12 78 6 1.29 88 8,156 4.1 22.1 64.2  Survival
17 29 F 8 L    80 1.5 15 60 10 1.86 320 7,752 3.1 102.0 60.3 n.e. Survival
18 17 M 11 L    110 3.6 6 80 3 0.96 50.6 1,531 1.3 87.3 26.5  Survival
19 74 M 8 L    152 2.9 7 78 3 0.19 120 309 0.6 20.2 10.2 n.e. Survival
20 83 F 11 E    100 2.2 12 74 8 1.19 130 5,316 2.6 60.6 35.6  Survival
21 33 M 20 E    90 1.2 16 62 13 1.03 270 2,564 2.7 34.0 20.6 n.e. Survival
22 36 M 5 L    118 3.6 10 76 6 1.11 131 3,201 2.9 56.0 23.3  Survival
BNP brain natriuretic peptide; CI cardiac index; CRP C-reactive protein; CS cardiogenic shock; cTnT cardiac troponin T; CVB3 coxsacklevirus B3; CVP central venous pressure; Day duration since flu-like symptoms
until admission; E  eosinophilic myocarditis; G  giant cell myocarditis; Hist  histology; IABP  intra-aortic balloon pump; IL  interleukin; L  lymphocytic myocarditis; n.e.  not examined; on AD  on admission; p AD
 post admission; PCPS  percutaneous cardiopulmonary support; PCWP  pulmonary capillary wedge pressure; SBP  systolic blood pressure; SVO2  mixed venous saturation; TNF-  tumor necrosis factor-alpha;   negative;
  positive.
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September 15, 2004:1292–7 IL-10 in Human Fulminant Myocarditisomparison of biochemical markers, including circu-
ating cytokines levels and hemodynamic variables on
dmission, between fulminant myocarditis and AMI.
erum levels of IL-10 and TNF-alpha in all patients with
ulminant myocarditis increased above the normal upper
imit on admission, but elevation of serum levels of IL-12
as observed in only 27% of patients (6 of 22) (Table 1).
erum IFN-gamma levels were within the normal range in
ll patients. This tendency was also observed in patients
ith AMI (data not shown).
Serum levels of IL-10 and TNF-alpha were significantly
igher in patients with fulminant myocarditis requiring
CSS during the acute phase than in patients with AMI
imilarly requiring MCSS (IL-10: 37.0  33.0 pg/ml vs.
3.7  11.4 pg/ml, p  0.025; TNF-alpha: 28.0  13.6
g/ml vs. 8.3  4.6 pg/ml, p  0.00014). There were no
ignificant differences in hemodynamic variables, including
lasma levels of BNP, between the two groups (Table 2).
omparison of biochemical markers, including circulat-
ng cytokines levels and hemodynamic variables on ad-
ission, among the subgroups of fulminant myocarditis.
irculating levels of BNP and cTnT were significantly
igher in group 1 than levels in groups 2 and 3 parallel with
he severity of circulatory failure. Serum levels of IL-10, but
ot other parameters, on admission were significantly
igher not only in group 1 but also in group 2 than levels in
roup 3 (49.1  37.5/20.7  17.6 pg/ml vs. 2.4  1.1
g/ml; p  0.0008/0.0012) (Table 3).
Further investigation from the viewpoint of mortality was
ndertaken, and it was discovered that serum levels of
L-10, but not TNF-alpha, were extremely higher in the
atal group than levels in the survival group of fulminant
yocarditis (74.0  27.0 pg/ml vs. 16.4  8.8 pg/ml; p 
.003) (Fig. 1A). Furthermore, serum IL-10 levels were also
able 2. Baseline Characteristics of Fulminant Myocarditis and
cute Myocardial Infarction on Admission
FMC
(n  14)
AMI
(n  15) p Value
ge (yrs) 50  17 55  25 NS
ale:female 8:6 13:2 NS
R (/min) 73  33 99  36 NS
BP (mm Hg) 86  17 83  24 NS
I (l/min/m2) 1.4  0.6 1.2  0.5 NS
CWP (mm Hg) 18.0 6.0 14.1  5.9 NS
VP (mm Hg) 12.4 3.0 10.0  4.1 NS
VO2 (%) 64.1  10.0 59.2  14.0 NS
ase excess (mEq/l) 2.9  5.2 3.4  6.6 NS
lasma BNP (pg/ml) 410  246 268  338 NS
erum CRP (g/dl) 6,466 5,103 2,147  2,897 0.047
erum Cr (mg/dl) 1.1 0.1 1.3  0.4 NS
erum IL-10 (pg/ml) 37.0 33.0 13.7  11.4 0.025
erum TNF- (pg/ml) 28.0  13.6 8.3  4.6 0.00014
alues are mean  SEM or number of patients.
AMI  acute myocardial infarction that similarly required mechanical circulatory
upport; Cr  creatinine; FMC  fulminant myocarditis that lapsed into cardiogenic
hock requiring mechanical circulatory support; HR  heart rate; other abbreviations
s in Table 1.igher in four non-survivors than in four survivors only in troup 1 (74.8  28.9 pg/ml vs. 19.9  13.0 pg/ml; p 
.01) (Table 1).
ISCUSSION
everal reports have discussed the predictive clinical param-
ters for the prognosis of acute myocarditis as a whole (13).
n this study, we focused on useful markers for the predic-
ion of fulmination requiring MCSS, because the prognosis
f patients with fulminant myocarditis requiring MCSS is
till unfavorable (6). In fact, patients in groups 1 and 2, who
apsed into severe HF requiring MCSS during the acute
hase, showed a much higher mortality rate than patients in
roup 3 without MCSS. In other words, these results
uggested that the severity of HF could be a factor deter-
ining the subsequent prognosis of fulminant myocarditis.
The prognosis of fulminant myocarditis in our study
opulation was poorer than that in the study of McCarthy
t al. (1): only 7% with fulminant myocarditis died during
ospitalization in McCarthy’s study, whereas 23% with
ulminant myocarditis died in ours (Table 1). Why was
here such a large difference in the prognosis? We can easily
how that 64% of patients required MCSS in the present
tudy, whereas only 13% did in the McCarthy et al. (1)
tudy. That is, differences in patient populations regarding
he severity of cardiac dysfunction and circulatory failure
ill lead to differences in prognosis in the two studies.
Higher levels of BNP and cTnT in group 1 with high
ortality suggested that BNP and cTnT, as markers for
everity of HF and myocardial damage, respectively, might
e useful prognostic markers for fulminant myocarditis. On
able 3. Baseline Characteristics in Subgroups of Fulminant
yocarditis on Admission
Group 1
(n  8)
Group 2
(n  6)
Group 3
(n  8)
ge (yrs) 54  17 43  15 49  25
ay 7  3 7 4 11 4
eart rate (/min) 74  22 76  33 77  31
BP (mm Hg) 73  4 104  9† 106  23†
I (l/min/m2) 1.0  0.2 2.1  0.2† 2.4  0.9†
CWP (mm Hg) 23  5 13 2† 11  4†
VP (mm Hg) 14  2 10 3† 7  3†
VO2 (%) 57  2 74 7† 72  8†
ase excess (mEq/l) 6.6  2.7 1.9  3.0† 0.8  3.0†
erum cTnT (ng/ml) 3.01 1.21 1.56  0.95* 1.25  0.65*
erum CRP (g/dl) 8,412 5,386 3,649  3,112 3,872  3,601
lasma BNP (pg/ml) 594  236 247  99† 176  104†
erum Cr (mg/dl) 1.1 0.1 1.1  0.1 1.0  0.2
erum IL-10 (pg/ml) 49.1 37.5 20.7  17.6‡ 2.4  1.1†
erum TNF- (pg/ml) 28.9  16.2 26.8  10.7 31.2  21.1
alues are mean  SEM. Group 1: fulminant myocarditis that had already lapsed
nto cardiogenic shock (CS) requiring mechanical cardiopulmonary support system
MCSS) with high-dose catecholamine (HCA) on admission; Group 2: fulminant
yocarditis that unexpectedly lapsed into CS requiring MCSS more than two days
fter HCA had started on admission to the hospital; Group 3: fulminant myocarditis
hat required only HCA but not MCSS. *p  0.05, †p  0.01 versus Group 1; ‡p 
.0012 versus Group 3.
cTnT  cardiac troponin T; Day  duration from flulike symptoms. Other
bbreviations as in Tables 1 and 2.he other hand, circulating levels of C-reactive protein, a
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IL-10 in Human Fulminant Myocarditis September 15, 2004:1292–7epresentative marker for the systemic inflammation, may
ot be available to predict higher mortality in view of the
esult that some survivors of group 1 revealed a rather mild
levation of C-reactive protein on admission and the eleva-
ion of C-reactive protein on admission could not distin-
igure 1. (A) Comparison of serum levels of interleukin (IL)-10 and tumor
ecrosis factor (TNF)-alpha on admission between non-survivors and
urvivors in fulminant myocarditis. Serum levels of IL-10, but not
NF-alpha, on admission increased considerably in five non-survivors
hen compared with levels in nine survivors of fulminant myocarditis with
ardiogenic shock requiring mechanical circulatory support. (B) Compar-
son of serum levels of IL-10 on admission between non-survivors and
urvivors in acute myocardial infarction. Serum levels of IL-10 on admis-
ion slightly increased in 5 non-survivors when compared with levels in 10
urvivors of acute myocardial infarction with cardiogenic shock requiring
echanical circulatory support. Solid bars and closed circles  mean 
EM; Open circles  data of subjects in the present study. AMI  acute
yocardial infarction; FMC  fulminant myocarditis.uish Group 1 from the other groups (Table 1). oThe present study showed that serum levels of IL-10 and
NF-alpha, but not always IL-12 and IFN-gamma, on
dmission increased above the normal upper limit in pa-
ients with myocarditis as well as with AMI. Furthermore,
erum IL-10 and TNF-alpha levels were significantly
igher in patients with myocarditis than those levels in
emodynamically equivalent patients with AMI. These data
mply that pathomechanistic factors other than HF, which
re found in myocarditis but not in AMI, must contribute to
he differing serum levels of these cytokines in the two
iseases, although previous reports demonstrated that serum
L-10 and TNF-alpha levels increased in patients with HF
hen compared with levels in normal subjects (16,17).
mong various biomarkers, only serum IL-10 levels on
dmission could distinguish group 2 from group 3. This
uggested that the increase of IL-10 could predict the
ppearance of severe CS requiring MCSS at an earlier stage
n fulminant myocarditis. In addition, the extremely higher
L-10 levels in fatal cases when compared with survivors
mong patients with fulminant myocarditis requiring
CSS (Fig. 1A), and the slightly higher IL-10 levels
mong patients with AMI (Fig. 1B), suggested that serum
evel of IL-10 on admission could also be a powerful
redictor of mortality in such a case with fulminant myo-
arditis, but not in AMI similarly requiring MCSS. Inter-
stingly, the serum IL-10 levels were also significantly lower
n survivors than levels in non-survivors only among group
patients (Table 1), suggesting that a lower IL-10 level is
possible marker for better prognosis of survival even in
imited cases with fulminant myocarditis with poor prog-
osis. Furthermore, the serum level of IL-10 in one non-
urvivor of group 2 was as high as levels in non-survivors of
roup 1 (Table 1). These findings might provide evidence to
emonstrate that serum IL-10 levels on admission reflect
ot only the severity of HF but also the outcome concerning
ortality.
It has been reported that the inhibition of natural killer
ells results in increased virus titers in the heart through
elayed virus clearance (18). Interleukin-10 inhibits the
roduction of IFN-gamma in natural killer cells, which has
een demonstrated in association with susceptibility to
rypanosoma cruzi-induced myocarditis (19,20). In addi-
ion, it has been shown that IL-10 is transcribed in the
yocardium parallel with viral replication in the acute and
hronic stages of experimental Coxsackievirus B3 viral
yocarditis (8,9). These findings suggest that the expres-
ion of myocardial IL-10 may reflect the persistence of
ctive myocardial viral infection and play a crucial role in the
evelopment of viral myocarditis. Interestingly, a closely
orrelated expression of virus and IL-10 in the acute stage of
urine viral myocarditis was also found in a spleen-
egulating, systemically immune response similar to that in
he heart (9). Hofmann et al. also reported that IL-10
xpression in human peripheral monocytes was strongly and
ersistently induced by Coxsackievirus B3 infection despite
nly slight production of other proinflammatory cytokines
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September 15, 2004:1292–7 IL-10 in Human Fulminant Myocarditisuch as TNF-alpha, IL-1, and IL-6 (21). This may suggest
hat an extreme elevation of serum levels of IL-10, rather
han TNF-alpha, on admission in human myocarditis can
eflect subsequent myocardial inflammation, which leads to
uture deterioration from the disease, through delayed
learance of the virus. On the other hand, some reports
sing experimental models have demonstrated a protective
ole of IL-10 in the development of acute myocarditis
11–13). This mechanism was explained by its suppressive
ffect against excessive immune response to viral infection or
subsequent autoimmune response leading to myocardial
njury. Extreme elevation of serum levels of IL-10 may
aradoxically reflect severe myocardial inflammation and
amage, which it is unable to modulate.
We could not completely confirm these hypotheses in all
ases reported here because of unproven direct viral infec-
ion. If myocardial IL-10 reflects active viral infection, the
iral antigen or genome might be identified in the myocar-
ial biopsy specimen using immunohistochemistry or re-
erse transcriptase-polymerase chain reaction (22). Unfor-
unately, there is no adequate form of myocardial material,
ncluding frozen tissue, for these purposes. This is a limi-
ation of the present study concerning a retrospective
nvestigation. However, prodrome, histologic findings, and
levation of virus titers (Table 1) could support the possi-
ility that subjects of myocarditis included here were af-
ected by viral infection.
ONCLUSIONS
he extreme elevation of serum levels of IL-10 on admis-
ion, which may reflect future progression of myocardial
nflammation in addition to cardiac dysfunction, enables
ne to determine not only the occurrence of CS requiring
echanical circulatory support but also the mortality in
atients with fulminant myocarditis.
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